Intuitive Surgical (ISRG)

Executive Summary

Intuitive Surgical is the global leader in robotic-assisted surgery, driven by its iconic da Vinci platform and expanding Ion bronchoscopy system. The company's high-margin recurring revenue model—from instruments, accessories, and services—underpins strong financial performance and a $161.64B market cap. With an installed base of over 8,000 da Vinci systems worldwide, Intuitive continues to penetrate new surgical specialties and geographies, while the Ion system captures lung biopsy market share. The company also invests in next-generation platforms and digital health integration, positioning it for sustained growth. However, competition from Medtronic, J&J, and emerging players, along with potential pricing pressures, temper the outlook. Overall, Intuitive Surgical maintains a dominant competitive moat and robust business model, justifying a high conviction score.

Upcoming Catalysts (preview)

• Q3 2026FDA approval and launch of da Vinci 5 (next-gen system) in key international markets90% success
• Q4 2026Positive clinical trial results for Ion in peripheral lung nodules leading to expanded indications75% success
• TBDPartnership or acquisition in digital surgery software or AI imaging60% success